A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) | MicrobiomeTrials← Back to trialsNCT07161544
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-09-29Est. Completion: 2032-07
Enrollment target: 75 participants Locations- Associated Retina Consultants, Phoenix, Arizona, United States
- Retina Vitreous Associates Medical Group, Los Angeles, California, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Retina Consultants of Texas, Bellaire, Texas, United States
- Retina Foundation of the Southwest, Dallas, Texas, United States
- Moorfields Eye Hospital NHS Foundation Trust, London, England, United Kingdom
- The Retina Clinic, London, England, United Kingdom
Other microbiome trials you might be interested in
Stargardt-Like Macular Dystrophy
Background:
STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have la…
Bethesda, United StatesEst. completion Jul 16, 2028
Retinal DegenerationABCA4-Related Retinopathies
Background:
\- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such a…
Bethesda, United States
ABCA4 RetinopathyStargardt DiseaseRetinal DystrophyRetinal Degeneration
Background:
ABCA4 retinopathy is a genetic disease in which the ABCA4 protein is absent or faulty. It can cause waste m…
Bethesda, United StatesEst. completion Feb 2, 2028